Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down's syndrome

British Journal of Pharmacology

Volumn 169, Issue 5, 2013, Pages 963-973

  Colas, D ^a   Chuluun, B ^a   Warrier, D ^a   Blank, M ^a   Wetmore, D Z ^a   Buckmaster, P ^a   Garner, C C ^a   Heller, H C ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

circadian; EEG; GABA; learning disability; long term memory; neuronal plasticity; novel object recognition; seizure sensitivity; Ts65Dn

Indexed keywords

PENTETRAZOLE; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN SYNDROME; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; LONG TERM MEMORY; MENTAL PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOGNITION; SHORT COURSE THERAPY; ANATOMY AND HISTOLOGY; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED; CIRCADIAN RHYTHM; COGNITION; DISEASE MODEL; DRUG EFFECTS; HIPPOCAMPUS; MALE; PATHOPHYSIOLOGY; PSYCHOLOGY; SEIZURE;

ANIMALS; BEHAVIOR, ANIMAL; CIRCADIAN RHYTHM; COGNITION; DISEASE MODELS, ANIMAL; DOWN SYNDROME; ELECTROENCEPHALOGRAPHY; GABA-A RECEPTOR ANTAGONISTS; HIPPOCAMPUS; MALE; MEMORY, LONG-TERM; MICE; PENTYLENETETRAZOLE; SEIZURES;

EID: 84879021945     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12169     Document Type: Article

References (59)

1. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324
2. Arima-Yoshida F, Watabe AM, Manabe T, (2011). The mechanisms of the strong inhibitory modulation of long-term potentiation in the rat dentate gyrus. Eur J Neurosci 33: 1637-1646.
3. Aschenbach EH, (1956). The use of metrazol in non-institutionalized elderly patients. Med Ann Dist Columbia 25: 70-72, passim.
4. Babiloni C, Albertini G, Onorati P, Muratori C, Buffo P, Condoluci C, et al. (2010). Cortical sources of EEG rhythms are abnormal in Down's syndrome. Clin Neurophysiol 121: 1205-1212.
5. Belichenko PV, Masliah E, Kleschevnikov AM, Villar AJ, Epstein CJ, Salehi A, et al. (2004). Synaptic structural abnormalities in the Ts65Dn mouse model of Down's syndrome. J Comp Neurol 480: 281-298.
6. Belichenko PV, Kleschevnikov AM, Masliah E, Wu C, Takimoto-Kimura R, Salehi A, et al. (2009). Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down's syndrome. J Comp Neurol 512: 453-466.
7. Blank M, Fuerst PG, Stevens B, Nouri N, Kirkby L, Warrier D, et al. (2011). The Down's syndrome critical region regulates retinogeniculate refinement. J Neurosci 31: 5764-5776.
8. Bliss TV, Lomo T, (1973). Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol 232: 331-356.
9. Braudeau J, Delatour B, Duchon A, Pereira PL, Dauphinot L, de Chaumont F, et al. (2011). Specific targeting of the GABA-A receptor alpha5 subtype by a selective inverse agonist restores cognitive deficits in Down's syndrome mice. J Psychopharmacol 25: 1030-1042.
10. Buckmaster PS, Lew FH, (2011). Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy. J Neurosci 31: 2337-2347.
11. Buzsaki G, Anastassiou CA, Koch C, (2012). The origin of extracellular fields and currents-EEG, ECoG, LFP and spikes. Nat Rev Neurosci 13: 407-420.
12. Chesrow EJ, Giacobe AJ, Wosika PH, (1951). Metrazol in arteriosclerosis associated with senility. Geriatrics 6: 319-323.
13. Colas D, Valletta JS, Takimoto-Kimura R, Nishino S, Fujiki N, Mobley WC, Mignot E, (2008). Sleep and EEG features in genetic models of Down syndrome. Neurobiol Dis 30: 1-7.
14. Colas D, Wagstaff J, Fort P, Salvert D, Sarda N, (2005). Sleep disturbances in Ube3a maternal-deficient mice modeling Angelman syndrome. Neurobiol Dis 20: 471-478.
15. Costa ACS, Grybko MJ, (2005). Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down's syndrome. Neurosci Lett 382: 317-322.
16. Davisson MT, Schmidt C, Akeson EC, (1990). Segmental trisomy of murine chromosome 16: a new model system for studying Down's syndrome. Prog Clin Biol Res 360: 263-280.
17. Deitrick RE, (1967). Pentylenetetrazol with nicotinic acid in the management of chronic brain syndrome. J Am Geriatr Soc 15: 191-195.
18. Delcroix J-D, Valletta J, Wu C, Howe CL, Lai C-F, Cooper JD, et al. (2004). Trafficking the NGF signal: implications for normal and degenerating neurons. Prog Brain Res 146: 3-23.
19. Dere E, Huston JP, De Souza Silva MA, (2007). The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 31: 673-704.
20. Diekelmann S, Born J, (2010). The memory function of sleep. Nat Rev Neurosci 11: 114-126.
21. Elliott R, Schneiderman N, (1968). Pentylenetrazol: facilitation of classical discrimination conditioning in rabbits. Psychopharmacologia 12: 133-141.
22. Faizi M, Bader PL, Tun C, Encarnacion A, Kleschevnikov A, Belichenko P, et al. (2011). Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down's syndrome: activation of β(1)-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol Dis 43: 397-413.
23. Fernandez F, Morishita W, Zuniga E, Nguyen J, Blank M, Malenka RC, et al. (2007). Pharmacotherapy for cognitive impairment in a mouse model of Down's syndrome. Nat Neurosci 10: 411-413.
24. Gardiner K, Herault Y, Lott IT, Antonarakis SE, Reeves RH, Dierssen M, (2010). Down's syndrome: from understanding the neurobiology to therapy. J Neurosci 30: 14943-14945.
25. Gross M, Finn MH, (1954). Oral metrazol therapy in psychotic senile and arteriosclerotic patients. J Am Geriatr Soc 2: 514-518.
26. Gurevicius K, Lipponen A, Tanila H, (2012). Increased cortical and thalamic excitability in freely moving APPswe/PS1dE9 mice modeling epileptic activity associated with Alzheimer's disease. Cereb Cortex 23: 1148-1158.
27. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
28. Holloway FA, Wansley R, (1973a). Multiphasic retention deficits at periodic intervals after passive-avoidance learning. Science (New York, NY) 180: 208-210.
29. Holloway FA, Wansley RA, (1973b). Multiple retention deficits at periodic intervals after active and passive avoidance learning. Behav Biol 9: 1-14.
30. Hunt E, Krivanek J, (1966). The effects of pentylenetetrazole and methylphenoxypropane on discrimination learning. Psychopharmacologia 9: 1-16.
31. Hunt EB, Bauer RH, (1969). Facilitation of learning by delayed injections of pentylenetetrazol. Psychopharmacologia 16: 139-146.
32. Kapernick JS, (1957). Metrazol for central nervous system arteriosclerosis in aging patients. Geriatrics 12: 703-708.
33. Kleschevnikov AM, Belichenko PV, Villar AJ, Epstein CJ, Malenka RC, Mobley WC, (2004). Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down's syndrome. J Neurosci 24: 8153-8160.
34. Krivanek J, McGaugh JL, (1968). Effects of pentylenetetrazol on memory storage in mice. Psychopharmacologia 12: 303-321.
35. Krivanek JA, (1971). Facilitation of avoidance learning by pentylenetetrazol as a function of task difficulty, deprivation and shock level. Psychopharmacologia 20: 213-229.
36. Levenga J, Willemsen R, (2012). Perturbation of dendritic protrusions in intellectual disability. Prog Brain Res 197: 153-168.
37. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
38. Marescaux C, Micheletti G, Vergnes M, Depaulis A, Rumbach L, Warter JM, (1984). A model of chronic spontaneous petit mal-like seizures in the rat: comparison with pentylenetetrazol-induced seizures. Epilepsia 25: 326-331.
39. Moore RY, Speh JC, (1993). GABA is the principal neurotransmitter of the circadian system. Neurosci Lett 150: 112-116.
40. Morris JK, Alberman E, (2009). Trends in Down's syndrome live births and antenatal diagnoses in England and Wales from 1989 to 2008: analysis of data from the National Down's syndrome Cytogenetic Register. BMJ 339: b3794.
41. Nadel L, (2003). Down's syndrome: a genetic disorder in biobehavioral perspective. Genes Brain Behav 2: 156-166.
42. Politoff AL, Stadter RP, Monson N, Hass P, (1996). Cognition-related EEG abnormalities in nondemented Down's syndrome subjects. Dementia 7: 69-75.
43. Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, et al. (1995). A mouse model for Down's syndrome exhibits learning and behaviour deficits. Nat Genet 11: 177-184.
44. Rissman RA, Mobley WC, (2011). Implications for treatment: GABAA receptors in aging, Down's syndrome and Alzheimer's disease. J Neurochem 117: 613-622.
45. Ruby NF, Hwang CE, Wessells C, Fernandez F, Zhang P, Sapolsky R, et al. (2008). Hippocampal-dependent learning requires a functional circadian system. Proc Natl Acad Sci U S A 105: 15593-15598.
46. Ruby NF, Fernandez F, Zhang P, Klima J, Heller HC, Garner CC, (2010). Circadian locomotor rhythms are normal in Ts65Dn Down's syndrome mice and unaffected by pentylenetetrazole. J Biol Rhythms 25: 63-66.
47. Rueda N, Flõrez J, Martínez-Cué C, (2008). Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down's syndrome. Neurosci Lett 433: 22-27.
48. Salehi A, Delcroix J-D, Belichenko PV, Zhan K, Wu C, Valletta JS, et al. (2006). Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51: 29-42.
49. Salehi A, Faizi M, Colas D, Valletta J, Laguna J, Takimoto-Kimura R, et al. (2009). Restoration of norepinephrine-modulated contextual memory in a mouse model of Down's syndrome. Sci Transl Med 1: 7ra17.
50. Siarey RJ, Carlson EJ, Epstein CJ, Balbo A, Rapoport SI, Galdzicki Z, (1999). Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down's syndrome. Neuropharmacology 38: 1917-1920.
51. Siarey RJ, Kline-Burgess A, Cho M, Balbo A, Best TK, Harashima C, et al. (2006). Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down's syndrome. J Neurochem 98: 1266-1277.
52. Siemen H, Colas D, Heller HC, Brustle O, Pera RA, (2011). Pumilio-2 function in the mouse nervous system. PLoS ONE 6: e25932.
53. Sutula T, He XX, Cavazos J, Scott G, (1988). Synaptic reorganization in the hippocampus induced by abnormal functional activity. Science 239: 1147-1150.
54. Velikova S, Magnani G, Arcari C, Falautano M, Franceschi M, Comi G, et al. (2011). Cognitive impairment and EEG background activity in adults with Down's syndrome: a topographic study. Hum Brain Mapp 32: 716-729.
55. Verpelli C, Sala C, (2011). Molecular and synaptic defects in intellectual disability syndromes. Curr Opin Neurobiol 22: 530-536.
56. Wang G, Grone B, Colas D, Appelbaum L, Mourrain P, (2012). Synaptic plasticity in sleep: learning, homeostasis and disease. Trends Neurosci 34: 452-463.
57. Yang Q, Rasmussen SA, Friedman JM, (2002). Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 359: 1019-1025.
58. Yoshiike Y, Kimura T, Yamashita S, Furudate H, Mizoroki T, Murayama M, et al. (2008). GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS ONE 3: e3029.
59. Yu T, Li Z, Jia Z, Clapcote SJ, Liu C, Li S, et al. (2010). A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum Mol Genet 19: 2780-2791.